In vitro basophil activation is reduced by short-term omalizumab treatment in hydrolyzed wheat protein allergy

• Yuko Chinuki,
• Akiko Yagami,
• Atsuko Adachi,
• Kayoko Matsunaga,
• Tsukasa Ugajin,
• Hiroo Yokozeki,
• Misa Hayashi,
• Ichiro Katayama,
• Kunie Kohno,
• Kuninori Shiwaku,
• Eishin Morita

Affiliations

Yuko Chinuki

Department of Dermatology, Shimane University Faculty of Medicine, Shimane, Japan; Corresponding author. Department of Dermatology, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, Shimane 693-8501, Japan.

Akiko Yagami

Department of Allergology, Fujita Health University School of Medicine, Aichi, Japan

Atsuko Adachi

Department of Dermatology, Hyogo Prefectural Kakogawa Medical Center, Hyogo, Japan

Kayoko Matsunaga

Department of Integrative Medical Science for Allergic Disease, Fujita Health University School of Medicine, Aichi, Japan

Tsukasa Ugajin

Department of Dermatology, Tokyo Medical and Dental University, Tokyo, Japan

Hiroo Yokozeki

Department of Dermatology, Tokyo Medical and Dental University, Tokyo, Japan

Misa Hayashi

Department of Dermatology, Osaka General Medical Center, Osaka, Japan

Ichiro Katayama

Department of Pigmentation Research and Therapeutics, Osaka City University, Osaka, Japan

Kunie Kohno

Department of Dermatology, Shimane University Faculty of Medicine, Shimane, Japan; Center for Community-Based Health Research and Education (COHRE), Organization for Research and Academic Information, Shimane University, Shimane, Japan

Kuninori Shiwaku

Shimane University Faculty of Medicine, Shimane, Japan

Eishin Morita

Department of Dermatology, Shimane University Faculty of Medicine, Shimane, Japan